Register Interest in Lung Test
Presently the Early-CDT® lung test is only available to medical doctors registered with Oncimmune LLC and located within the USA or Canada. The company plans to launch the test in other countries during 2012 but recognises that there will be interest before this happens.
We are able to register your interest in having the test when it becomes available in your country. By clicking on the 'Register Interest' tab you will be prompted to supply personal details including a brief medical history. This information will be stored securely and will only be used as a method of contact for those wishing to take the test. If, at any point, you (or your nominated other) would like your details deleted from our system please click on the 'Unsubscribe' tab.
Patients
Understanding EarlyCDT®
How EarlyCDT® Works
Cancerous tumors produce protein molecules known as —“markers”. These proteins are also called “antigens.”
This is how EarlyCDT® works:
- Antigens are certain by–products from cancer cells that are produced very early in a tumor's development, and they trigger the body's immune system to respond.
- The immune system releases autoantibodies to fend off these antigens.
- The immune system produces many more autoantibodies than the tumor does antigens, making the autoantibodies easier to detect than the antigens.
- The immune system does not normally produce antibodies against normal tissue proteins; therefore, these autoantibodies to cancerous tissue antigens provide high specificity.
- EarlyCDT® measures autoantibodies produced in response to a number of antigens associated with a particular type of tumor.
- The measurement of autoantibodies provides an early indication that a tumor exists, thus improving the potential for saving a life.
EarlyCDT® is performed only in an Oncimmune® laboratory using a small blood sample. The Oncimmune® USA laboratory follows regulations set forth by the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Congress enacted these amendments to ensure quality laboratory testing in the United States.
However, blood samples can be drawn anywhere in the world and sent to our laboratory to have the test performed.
What EarlyCDT® Results Mean
Two (2) results are possible from EarlyCDT®: positive or negative. A negative EarlyCDT® result means no cancer of the type being tested for can be detected at the time of testing.
A positive EarlyCDT® result indicates that autoantibodies to one or more of the cancer antigens in the EarlyCDT® panel exist in quantities exceeding a cutoff value suggesting that a tumor could be present. Your healthcare provider will work with you to devise a plan to ensure the earliest possible diagnosis and intervention.